The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to Krystal Biotech’s KB707 program on February 9 2026. KB707 is a nebulized inhaled gene therapy that delivers interleukin‑12 and interleukin‑2 directly into the lung tumor microenvironment, targeting non‑small cell lung cancer (NSCLC). The RMAT status signals the FDA’s confidence in the program’s safety and efficacy profile and opens a pathway for accelerated development and review.
RMAT designation provides several practical advantages. It allows the company to engage in a more collaborative review process, including the possibility of rolling review and more frequent FDA guidance. The designation also signals that the program meets the 21st Century Cures Act criteria for serious or life‑threatening diseases, which can shorten the time to approval and reduce development costs. The decision was supported by data from the Phase 1/2 KYANITE‑1 trial, which reported objective response rates of 27 % to 36 % in heavily pre‑treated NSCLC patients and a manageable safety profile with most adverse events being Grade 1 or 2.
The regulatory milestone expands Krystal Biotech’s portfolio beyond its commercialized product VYJUVEK, a gene therapy for dystrophic epidermolysis bullosa. KB707’s RMAT status positions the company to tap into the large, unmet NSCLC market and marks the second RMAT designation for the company, underscoring its experience with accelerated pathways. The designation also enhances investor and partner confidence, as reflected in recent analyst upgrades and price‑target increases.
Krystal Biotech recently reported Q4 2025 and full‑year 2025 financial results. Net revenue for Q4 was $106‑$107 million and for the full year was $388‑$389 million, slightly below estimates. The company is scheduled to report its Q4 and full‑year 2025 results on February 17 2026. Analysts have raised price targets, citing the company’s potential to become a multi‑product business and the accelerated development path for KB707.
Following the RMAT announcement, analysts upgraded their outlooks and raised price targets, citing the accelerated development potential and the strength of early clinical data. The market reaction was driven primarily by the regulatory milestone and the company’s expanding pipeline, which together suggest a more favorable long‑term trajectory for Krystal Biotech.
Suma Krishnan, President of Research and Development, said the RMAT designation reflects the urgent unmet need for new NSCLC therapies and the promising early data. She added that the designation is a testament to the company’s ability to navigate the regulatory landscape and accelerate development.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.